Part two
{MY comments are in BLUE}
I did not include all the financial numbers- those are available on any financial website.
Financial Summary (Frank):
1. We're in our 2025 planning process now, but I can tell you we expect to make additional investments in sales and marketing, and we continue to explore the most effective ways of utilizing outsourced foundry services. So, our non-GAAP opex in 2025 will be higher than this year, likely in the range of $16 million to $17 million. We'll provide more color on this in our next quarterly update call.
{I'm not sure how to read this. I mean, close a deal and sales will follow. Spend more on "Marketing"?? Maybe someone reading this can shed some light on why Atomera would be trying to strengthen that aspect of the business. I'm medical background- not business}
1. Chips Funding- In July, we submitted a funding proposal related to our work on GaN and other compound semiconductors, but no decisions have been made on that yet. We expect that the next phase of the RFP will be announced in late Q4 or Q...and our technology is compelling to various government departments.
{Frank does discuss projected funding for the upcoming year but he does it in the Q&A section. The gist is this: "...we need to maintain a minimum cash balance of greater than 12 months of what we plan to spend in the future."}
Scott’s closing summary of Frank’s comments- "Thanks a lot, Frank. From today's call, I hope you have a sense of the building momentum that we're feeling. Right now is a very exciting time to be part of the Atomera story. Our technology is being sought out by some of the biggest players in the industry.It's perfectly aligned with several industry trends and should form a very strong growth engine on top of the revenue base that we hope to build with ST as our foundation."

Recent ATOM News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/19/2025 08:04:27 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/19/2025 08:02:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2025 04:49:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2025 11:01:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2025 11:00:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2025 10:10:48 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/04/2025 09:32:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2025 12:41:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2025 12:41:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2025 12:40:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2025 12:40:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2025 09:45:11 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2025 09:02:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/28/2025 09:02:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2024 09:01:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/03/2024 09:00:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/03/2024 09:00:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/03/2024 09:00:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/29/2024 08:47:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2024 08:45:37 PM
- Atomera Collaborates With the Center for Integrated Nanotechnologies (CINT) at Sandia National Laboratories to Validate MST’s Ability to Address GaN Manufacturing Challenges • Business Wire • 10/08/2024 09:05:00 PM
- Media Alert: Atomera to Deliver Presentation on Applications of Oxygen Inserted Epitaxy at PRiME 2024 • Business Wire • 10/07/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 11:08:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 11:07:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 11:03:15 PM
LaFleur Minerals Provides Update on Beacon Mill Restart, Results of Annual General and Special Meeting, and Swanson Gold Deposit Exploration and Drilling Updates • LFLRF • Mar 21, 2025 9:40 AM
Basanite Industries, Inc. Appoints Michael D. Nelson as Chief Executive Officer • BASA • Mar 21, 2025 9:01 AM
Fifty 1 Labs, Inc. (FITY) Acquires Genetic Networks, Working to Secure Multi-Million Dollar DoD Contracts, and Positions for Rapid Expansion in Biotech Innovation • FITY • Mar 20, 2025 9:00 AM
VAYK Forms Partnership with Airbnb Investing Group to Offer Service Solution • VAYK • Mar 20, 2025 9:00 AM
4Cable TV International, Inc. (CATV) Facilitates Acquisition of Genetic Networks LLC by Fifty 1 Labs, Inc. (FITY), Announces Dividend for CATV Shareholders, and Sets Stage for Transformative Reverse Merger • CATV • Mar 20, 2025 8:30 AM
NUBURU Announces Elimination of 100% of its Long-Term Indebtedness and $5.15 Million Strategic Investment in Supply@ME Capital • BURU • Mar 19, 2025 8:53 AM